ProShare Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $419K | Sell |
44,029
-3,575
| -8% | -$27.8K | ﹤0.01% | 1162 |
|
|
2025
Q4 | $371K | Buy |
47,604
+4,307
| +10% | +$31.1K | ﹤0.01% | 1319 |
|
|
2025
Q3 | $329K | Sell |
43,297
-7,448
| -15% | -$62K | ﹤0.01% | 1361 |
|
|
2025
Q2 | $455K | Sell |
50,745
-3,413
| -6% | -$31.8K | ﹤0.01% | 1175 |
|
|
2025
Q1 | $406K | Sell |
54,158
-13,846
| -20% | -$112K | ﹤0.01% | 1209 |
|
|
2024
Q4 | $511K | Buy |
68,004
+16,732
| +33% | +$127K | ﹤0.01% | 1257 |
|
|
2024
Q3 | $390K | Buy |
51,272
+13,144
| +34% | +$99.9K | ﹤0.01% | 1294 |
|
|
2024
Q2 | $236K | Sell |
38,128
-10,375
| -21% | -$57.3K | ﹤0.01% | 1444 |
|
|
2024
Q1 | $246K | Buy |
48,503
+4,041
| +9% | +$22.7K | ﹤0.01% | 1544 |
|
|
2023
Q4 | $266K | Buy |
44,462
+7,450
| +20% | +$43.2K | ﹤0.01% | 1465 |
|
|
2023
Q3 | $262K | Buy |
37,012
+134
| +0.4% | +$963 | ﹤0.01% | 1283 |
|
|
2023
Q2 | $260K | Buy |
36,878
+1,981
| +6% | +$15.9K | ﹤0.01% | 1366 |
|
|
2023
Q1 | $291K | Sell |
34,897
-4,388
| -11% | -$42.2K | ﹤0.01% | 1230 |
|
|
2022
Q4 | $451K | Buy |
39,285
+3,202
| +9% | +$39.9K | ﹤0.01% | 1010 |
|
|
2022
Q3 | $455K | Buy |
36,083
+790
| +2% | +$10.2K | ﹤0.01% | 937 |
|
|
2022
Q2 | $374K | Sell |
35,293
-17,576
| -33% | -$181K | ﹤0.01% | 1087 |
|
|
2022
Q1 | $860K | Sell |
52,869
-11,704
| -18% | -$188K | ﹤0.01% | 977 |
|
|
2021
Q4 | $894K | Buy |
64,573
+3,575
| +6% | +$47.3K | ﹤0.01% | 1092 |
|
|
2021
Q3 | $877K | Sell |
60,998
-17,056
| -22% | -$269K | ﹤0.01% | 949 |
|
|
2021
Q2 | $1.23M | Buy |
78,054
+6,380
| +9% | +$86.7K | ﹤0.01% | 917 |
|
|
2021
Q1 | $729K | Buy |
71,674
+5,294
| +8% | +$54.6K | ﹤0.01% | 1187 |
|
|
2020
Q4 | $495K | Buy |
66,380
+16,273
| +32% | +$83.9K | ﹤0.01% | 1282 |
|
|
2020
Q3 | $172K | Buy |
50,107
+1,488
| +3% | +$6.38K | ﹤0.01% | 1445 |
|
|
2020
Q2 | $232K | Buy |
48,619
+18,414
| +61% | +$73.5K | ﹤0.01% | 1371 |
|
|
2020
Q1 | $60K | Sell |
30,205
-23,188
| -43% | -$63.8K | ﹤0.01% | 1109 |
|
|
2019
Q4 | $184K | Buy |
53,393
+10,952
| +26% | +$27.6K | ﹤0.01% | 1612 |
|
|
2019
Q3 | $122K | Sell |
42,441
-1,314
| -3% | -$4.09K | ﹤0.01% | 1525 |
|
|
2019
Q2 | $166K | Sell |
43,755
-5,356
| -11% | -$32.2K | ﹤0.01% | 1474 |
|
|
2019
Q1 | $400K | Buy |
49,111
+451
| +0.9% | +$3.86K | ﹤0.01% | 1121 |
|
|
2018
Q4 | $393K | Sell |
48,660
-9,293
| -16% | -$72.3K | ﹤0.01% | 1034 |
|
|
2018
Q3 | $442K | Buy |
57,953
+3,451
| +6% | +$23.2K | ﹤0.01% | 1164 |
|
|
2018
Q2 | $312K | Sell |
54,502
-3,533
| -6% | -$19.4K | ﹤0.01% | 1363 |
|
|
2018
Q1 | $277K | Sell |
58,035
-9,526
| -14% | -$48.9K | ﹤0.01% | 1365 |
|
|
2017
Q4 | $332K | Buy |
67,561
+16,754
| +33% | +$81.2K | ﹤0.01% | 1331 |
|
|
2017
Q3 | $266K | Buy |
50,807
+2,453
| +5% | +$12.6K | ﹤0.01% | 1183 |
|
|
2017
Q2 | $269K | Buy |
48,354
+427
| +0.9% | +$2.6K | ﹤0.01% | 1223 |
|
|
2017
Q1 | $403K | Sell |
47,927
-12,600
| -21% | -$87.6K | ﹤0.01% | 1097 |
|
|
2016
Q4 | $383K | Buy |
60,527
+6,790
| +13% | +$35.3K | ﹤0.01% | 1226 |
|
|
2016
Q3 | $237K | Sell |
53,737
-10,106
| -16% | -$40.4K | ﹤0.01% | 1262 |
|
|
2016
Q2 | $181K | Buy |
63,843
+876
| +1% | +$2.72K | ﹤0.01% | 1449 |
|
|
2016
Q1 | $178K | Sell |
62,967
-6,565
| -9% | -$29.1K | ﹤0.01% | 1446 |
|
|
2015
Q4 | $718K | Buy |
69,532
+6,755
| +11% | +$67.2K | 0.01% | 876 |
|
|
2015
Q3 | $716K | Sell |
62,777
-4,319
| -6% | -$57.6K | 0.01% | 788 |
|
|
2015
Q2 | $1M | Sell |
67,096
-4,345
| -6% | -$49.4K | 0.01% | 775 |
|
|
2015
Q1 | $645K | Buy |
71,441
+8,864
| +14% | +$91.8K | 0.01% | 1060 |
|
|
2014
Q4 | $761K | Sell |
62,577
-2,165
| -3% | -$23.9K | 0.01% | 990 |
|
|
2014
Q3 | $633K | Sell |
64,742
-11,866
| -15% | -$145K | 0.01% | 1265 |
|
|
2014
Q2 | $977K | Buy |
76,608
+31,373
| +69% | +$305K | 0.01% | 1175 |
|
|
2014
Q1 | $479K | Buy |
45,235
+19,349
| +75% | +$206K | 0.01% | 1901 |
|
|
2013
Q4 | $197K | Buy |
+25,886
| New | +$164K | ﹤0.01% | 1260 |
|
|
2013
Q3 | – | Sell |
-34,599
| Closed | -$54K | – | 2526 |
|
|
2013
Q2 | $54K | Buy |
+34,599
| New | +$59.7K | ﹤0.01% | 2351 |
|
Other funds holding BCRX
RCM
DM
VPM
VCM
TCM
PA
VPC
ProShare Advisors's BCRX Position: Q1 2026 in Review
ProShare Advisors reduced its BioCryst Pharmaceuticals (BCRX) stake by 7.5% in Q1 2026, selling an estimated $27.8K and leaving 44,029 shares worth $419K. The position accounts for ﹤0.01% of the portfolio, ranked #1162.
ProShare Advisors first reported a position in BCRX in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.23M in Q2 2021. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.
- ProShare Advisors held 44,029 shares of BioCryst Pharmaceuticals worth $419K as of Q1 2026.
- ProShare Advisors sold 3,575 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $27.8K.
- BioCryst Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1162 holding.
- ProShare Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- ProShare Advisors's BioCryst Pharmaceuticals position peaked at $1.23M in Q2 2021.
- 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.
Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.